- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02112422
The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.
연구 개요
상세 설명
Dexamethasone, a potent synthetic glucocorticoid with minimal mineralocorticoid effects, is commonly administered as an anesthesia adjunct for the prevention of postoperative nausea and vomiting (PONV). Over the last two decades the analgesic effects of dexamethasone have also been demonstrated in the treatment of acute and chronic pain. Two recent meta-analyses of over thirty randomized clinical trials (close to 5,000 subjects) concluded that dexamethasone at doses more than 0.1 mg/kg is an effective adjunct in multimodal strategies to reduce postoperative pain and opioid consumption after a variety of surgeries.
Cesarean section is a common surgical procedure and associated with a moderate amount of postoperative pain (Visual analogue score (VAS) of 3-5, on a 10 point scale). Patients' postoperative experience closely correlates with their perception of pain management. Controlling postoperative pain after cesarean section remains an important clinical challenge. A multimodal approach to reduce pain has become a standard of care and includes varying doses of intrathecal local anesthetic, intrathecal morphine, co-administration of opioids or other adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Dexamethasone is typically administered in the elective cesarean section population for the prevention of intrathecal opioid induced PONV. Recently however, the potential benefit of single dose dexamethasone has been demonstrated in improving postoperative analgesia in this patient population.
The analgesic effect of dexamethasone in post-cesarean section parturients is likely to be mediated via its anti-inflammatory actions. This does not come as a surprise given the profound inflammatory changes associated with the peripartum period and cesarean sections. Until the late third trimester. pregnancy is thought to be associated with suppression of a variety of humoral and cell-mediated immunological functions to accommodate the "foreign" semi-allogeneic fetal graft. The proinflammatory milleu becomes up regulated in late pregnancy and around the time of delivery. Specifically, during the third trimester, the percentage of granulocytes and cluster of differentiation 8 (CD8+) T lymphocytes are significantly increased, along with a concomitant reduction in the percentages of cluster of differentiation 4 (CD4+) T lymphocytes and monocytes. During the peripartum and delivery period, leukocyte count may become markedly elevated, attaining levels of 25,000/μL or greater. Moreover, circulating leukocytes undergo significant phenotypic changes including the upregulation of adhesion molecules. Other markers of inflammation including C-reactive protein, erythrocyte sedimentation rate (ESR) and complement factors C3 and C4 are all increased in normal pregnancy and significantly so during labour.
Cesarean section itself causes significant surgical stress and results in a profound inflammatory response. Inflammation is triggered not only by direct tissue injury from surgical incision and deeper tissue trauma but also by "spillage" of highly pro-inflammatory mediators from amniotic fluid and placental tissue into the pelvic cavity as well as systemic circulation.
As a result of the inflammatory insults of pregnancy and cesarean section, dexamethasone has emerged as an important adjunct in postoperative pain control in this patient population. Unanswered, however, is the role that the timing of dexamethasone administration may play in its analgesic action. Dexamethasone peak effect is delayed by 60-90 minutes reflecting its unique pharmacodynamics. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and protein synthesis. This leads to inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. Direct anti-inflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins and lipocortins (which control the biosynthesis prostaglandins and leukotrienes). This multistep mechanism of action may explain why administration of dexamethasone prior to the stress of surgery may optimize its therapeutic effects including analgesia and anti-emesis. However, the vast majority of studies on dexamethasone administer the drug immediately prior to or during surgery.
The purpose of this randomized, double-blinded trial is to determine if single dose dexamethasone given 45-60 minutes preoperatively reduces VAS pain scores and improves quality of recovery in patients undergoing elective cesarean section as compared to the same dose given immediately after surgical incision.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3A1R9
- Health Sciences Center
-
Winnipeg, Manitoba, 캐나다, R3Y-0A9
- Winnipeg Health Sciences Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
•Over 18 years of age
- American Society of Anesthesiologists class I-III
- Presenting for elective cesarean section.
Exclusion Criteria:
•Contraindication to regional anesthesia
- Allergy to study drug
- Uncontrolled diabetes
- Active infection
- Adrenal axis pathology
- Active treatment with steroids
- Treatment with oral or parenteral steroids within the previous 6 months
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 단일 그룹 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Control
Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
|
The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
다른 이름들:
|
|
실험적: Intervention
Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
|
Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Postoperative Pain using visual analogue score.
기간: 24 hours
|
24 hours
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of episodes of Nausea and Vomiting
기간: 24 hours post-operative
|
24 hours post-operative
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- B2013:159
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
임신에 대한 임상 시험
-
The Nazareth Hospital, Israel완전한Streptococcus B Carrier State Complicating Pregnancy이스라엘
Control에 대한 임상 시험
-
Gonzalo Jorquera, PhDUniversidad de Valparaiso완전한
-
Anglia Ruskin UniversityDanone Global Research & Innovation Center완전한
-
Hacettepe University아직 모집하지 않음
-
Ryme Medical, Inc.아직 모집하지 않음COPD | 폐질환, 만성 폐쇄성 | COPD 환자 | COPD 급성 악화 | COPD(만성폐쇄성폐질환) | 폐 질환 항공 | COPD 악화
-
Indiana UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)종료됨
-
Khyber Medical University PeshawarKhyber Teaching Hospital; Northwest General Hospital and Research centre모병
-
Rethink Medical SLEvidenze Health España (CRO); Centro para el Desarrollo Tecnológico y la Innovación (CDTI)...정지된
-
University of Sao PauloGrand Challenges Canada; Fundaçao Maria Cecilia Souto Vidigal빼는